Screener / SEC EDGAR /CIK 0000009326 /10-K filed Feb 20, 2026, compared with Feb 21, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Materials · Chemicals & Allied Products

Balchem Corp BCPC

Compare with peers Embed
SEC comment letters, last 20 years

4 reviews of BCPC's filings by SEC staff

UPLOAD and CORRESP
Reviews 4 latest letter Oct 5, 2018
Questions asked 39 each answered in the company's own letter
No closing letter 0 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 5 UPLOAD
  2. 2. Questions in them 39 numbered comments
  3. 3. Company replies 6 CORRESP
  4. 4. Reviews closed 4 of 4 closing letter

Half the closed reviews took 44 days or less from the first letter to the closing letter.

Form 10-Q

2018-10-05 to 2018-11-01 · 4 questions · 1 letter from the SEC, 1 from the company
Review closed 2018-11-01
Revenue
Financial Statements · Note 12- Revenue, page 23
SEC asked (1)
Please tell us how you considered the disclosure requirements of ASC 606-10-50-8 and ASC 606-10-50-12 as it relates to your contract balances and performance obligations.
BCPC answered
We believe that we have met the disclosure requirements under ASC 606-10-5-8. We present the opening and closing balances of receivables on the face of the Condensed Consolidated Balance Sheets. In review of our revenue streams in connection with the implementation of ASC 606, we have determined that all product sales (including co-manufacturing, bill and hold, and consignment), which represent the overwhelming majority of total revenue, are point in time sales.
Rest of the answer

We do not have significant other contract assets besides receivables, and contract liabilities are insignificant as all performance obligations are satisfied when control of the goods is transferred to our customers. Because this is not material to our operations, disclosure of the opening and closing balances of the contract assets and contract liabilities, as well as the revenue recognized in the reporting period that was included in the contract liability balance at the beginning of the period, is not deemed necessary.

We believe that we have also met the disclosure requirements under ASC 606-10-50-12. We disclosed in Note 12 that “revenues are recognized when control of the promised goods is transferred to our customers” and “Balchem’s primary operation is the manufacturing and sale of health and wellness ingredient products, in which Balchem receives an order from a customer and fulfills that order”. These statements describe the company’s performance obligations, the nature of the goods provided, and when those obligations are satisfied. Further disclosure related to the satisfaction of performance obligations under bill-and-hold arrangements and royalty agreements was deemed unnecessary as the total amount of revenue recorded under these arrangements is not material to our operations. We have also disclosed a description of our payment terms with customers, which typically range from 30 to 120 days. We do not have any significant financing components to our payment terms, significant obligations for returns or refunds, or obligations related to warranties. We have also determined that variable consideration, primarily consisting of rebates based on volume achievement milestones and discounts taken as part of payment terms, are not material to our operations. As such, we concluded that disclosure of these items is not required.

Read in the reply
In its next report

First report after the company's reply of Oct 19, 2018: 10-Q filed Nov 6, 2018 ↗, against the 10-Q filed Aug 3, 2018 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Financial Statements · Note 12- Revenue, page 23
SEC asked (2)
Please address your consideration of ASC 606-10-55-36 through 55-40 for your comanufacturing revenue source.
BCPC answered
We have reviewed the principal versus agent considerations provided in ASC 606-10-55-36 through ASC 606-10-55-40 as it relates to our co-manufacturing revenue source. Under the co-manufacturing agreements, we are responsible for the manufacture of a finished good where the customer provides some or all of the raw materials. We control the manufacturing process and the ultimate end product before it is shipped to the customer. We are responsible for meeting customer specifications, have inventory risk before transferring it to the customer, and have discretion in establishing prices.
Rest of the answer

Additionally, we do not use third parties in the co-manufacturing process. Based on these factors, we have determined that we are the Principal in these agreements and therefore it is appropriate to recognize revenue in the gross amount of consideration we expect to be entitled for the goods and services provided.

To provide further clarity the Company will include a disclosure similar to the following example in Future Filings:

"Under the co-manufacturing agreements, Balchem is responsible for the manufacture of a finished good where the customer provides some or all of the raw materials. The Company controls the manufacturing process and the ultimate end product before it is shipped to the customer. Based on these factors, we have determined that we are the Principal in these agreements and therefore revenue is recognized in the gross amount of consideration we expect to be entitled for the goods provided."

Read in the reply
In its next report

First report after the company's reply of Oct 19, 2018: 10-Q filed Nov 6, 2018 ↗, against the 10-Q filed Aug 3, 2018 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Financial Statements · Note 12- Revenue, page 23
SEC asked (3)
We note that you do not disclose the value of unsatisfied performance obligations for contracts where you recognize revenue at the amount to which you have the right to invoice for products shipped. In that regard, it appears that you are applying the practical expedient afforded under ASC 606-10-55-18.
Rest of the question

To the extent you are, please clarify to which of your revenue sources you are applying the practical expedient and how you determined that recognizing revenue over time was appropriate. See ASC 606-10-25-27. To the extent you have determined you have performance obligations that are satisfied over time, please also provide the disclosures in ASC 606-10-50-18.

BCPC answered
We have reviewed our revenue sources and determined that all product sales (including co-manufacturing, bill and hold, and consignment) are point in time sales. Unsatisfied performance obligations are not material to our operations as our performance obligations are satisfied when control of the goods is transferred to our customers. As such, we concluded that disclosure for unsatisfied performance obligations is not necessary. We have determined that our only revenue stream that has performance obligations that are satisfied over time is royalty revenue.
Rest of the answer

The Company is using historical data and minimums to record royalty revenues based on the guidance provided in FASB Staff Paper, “Sales-Based or Usage-Based royalty with Minimum Guarantee” to recognize royalty revenue. Total royalty revenue is not material to our operations. As such, disclosures related to the methods used to recognize revenue and an explanation of why the methods used provide a faithful depiction of the transfer of services are not deemed necessary, as we do not believe it will provide value to the users of the financial statements.

Read in the reply
In its next report

First report after the company's reply of Oct 19, 2018: 10-Q filed Nov 6, 2018 ↗, against the 10-Q filed Aug 3, 2018 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Note 18 - Related Party Transactions, page 63
SEC asked (4)
Your disclosures indicate that your sales and service transactions with St. Gabriel CC Company, LLC, an equity method investee, are netted against purchases of finished goods from St. Gabriel CC Company LLC in cost of goods sold. Please more fully explain your accounting for these transactions, including the accounting literature on which you are relying.
Rest of the question

Also, given these disclosures, it is not clear to us how your discussion in Net Sales on page 19, that indicates 2016 sales were positively impacted by sales to St. Gabriel CC Company, LLC in advance of the joint venture becoming operational, is appropriate. Please advise.

BCPC answered
The substance of the raw materials provided to St. Gabriel CC Company, LLC is connected to the understanding that the Company is purchasing finished goods that use these same raw materials, which will ultimately be sold to an unrelated, external customer. As such, the sale of raw materials to St. Gabriel CC Company, LLC in this scenario lacks economic substance. We determined that it was appropriate to net these sales against the purchases of finished goods so as not to inflate sales for a transaction that lacks economic substance.
Rest of the answer

We refer to “Speech by SEC Staff: Revenue Recognition” by Lynn E. Turner,

Chief Accountant – U.S. Securities & Exchange Commissions, on May 31, 2001, which discusses the following: “…the company must receive from its customer a separately identifiable benefit that the company could have obtained from a third party, and there must be sufficient, competent and verifiable evidence of the fair value of the benefit received. When an entity would not have entered into one of the separate contracts without all the contracts being negotiated and agreed to as a

“package”, it will often be difficult to identify a separable benefit being received and to establish reliable and verifiable fair values for each element of the arrangement. In those instances, the facts and circumstances will often dictate that the cash inflows and outflows be reported as a net revenue or cost amount, in the appropriate periods.” We believe that the substance of the transactions with St. Gabriel CC Company, LLC meet the spirit of the guidance provided in this speech.

Further supporting this position is the fact that we are not in the business of selling these raw materials to other external customers.

Additionally, we advise the Staff that our comment on Net Sales on page 19 refers to external sales to our partner in the St. Gabriel

CC Company, LLC joint venture, and does not refer to sales to the St. Gabriel CC Company, LLC joint venture itself. Prior to the joint venture becoming operational, we sold aqueous choline to this partner directly. These sales no longer occurred in fiscal year ended December 31, 2017, which partially offset the overall increase in sales for the segment.

“The Company provides services on a contractual agreement to St. Gabriel CC Company, LLC. These services include accounting, information technology, quality control, and purchasing services, as well as operation of the St. Gabriel CC Company, LLC plant. The Company also sold raw materials to St. Gabriel CC Company, LLC. In return, St. Gabriel CC Company, LLC provides choline chloride finished goods. The substance of the raw material provided to St. Gabriel CC Company, LLC is connected to the understanding that the Company is purchasing finished goods that use these same raw materials, which will ultimately be sold to an unrelated, external customer. As such, the sale of raw materials to St. Gabriel CC Company, LLC in this scenario lacks economic substance.

The services the Company provided amounted to $3,445 and $1,837, respectively, for the years ended December 31, 2017 and 2016. The raw materials sold amounted to $23,459 and $7,480, respectively, for the years ended December 31, 2017 and 2016. The raw materials sold amounted to $23,459 and $7,480, respectively, for the years ended December 31, 2017 and 2016. These services and raw materials are primarily recorded, net of the finished goods received from St. Gabriel CC Company, LLC of $20,827 and $8,619, respectively for the years ended December 31, 2017 and 2016, in cost of goods sold. At December 31, 2017, the Company had a receivable of $6,190, recorded in accounts receivable from St. Gabriel CC Company, LLC for services rendered and raw materials sold and a payable of $4,112 for finished goods received. In addition, the Company had a payable in the amount of $363 related to non-contractual monies owed to St. Gabriel CC Company, LLC, recorded in accrued expenses.”

To provide further clarity in the MD&A, the Company will expand our disclosure in Future Filings similar to the following example:

“Net sales for the Industrial Products segment were $47,951 for the year ended December 31, 2017, an increase of $23,126 or 93.2%. The increase is principally due to higher sales of various choline and choline derivatives used in shale fracking applications. Prior to the St. Gabriel CC Company, LLC joint venture becoming operational, the Company sold aqueous choline to our partner in the joint venture directly. As such, these sales no longer occurred in the year ended December 31, 2017, which partially offset the overall increase in sales for the segment.”

Read in the reply
In its next report

First report after the company's reply of Oct 19, 2018: 10-Q filed Nov 6, 2018 ↗, against the 10-Q filed Aug 3, 2018 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2018-11-01

Form 10-K for the Year ended December 31, 2010

2011-12-06 to 2011-12-29 · 7 questions · 1 letter from the SEC, 2 from the company
Review closed 2011-12-29
SegmentsResults discussion (MD&A)Liquidity and cash
Form 10-K for the Year Ended December 31, 2010 · General
SEC asked (1)
Where a comment below requests additional disclosures or other revisions to be made, please show us in your supplemental response what the revisions will look like. These revisions should be included in your future filings.
BCPC answered
We agree to provide the additional disclosures or revisions as noted in the response below in our future filings with the Commission on Form 10-K and Form 10-Q, as applicable. Sample disclosures, for illustration purposes only, are included below as appropriate.
Read in the reply
Operations, page 12 · Fiscal Year 2010 Compared to Fiscal Year 2009
SEC asked (2)
Please discuss in greater detail the business reasons for the changes between periods in your net sales and operating expenses line items. In doing so, please disclose the amount of each significant change in line items between periods and the business reasons for it.
Rest of the question

In circumstances where there is more than one business reason for the change, attempt to quantify the incremental impact of each individual business reason discussed on the overall change in the line item. For example, it is unclear what impact the increase in volumes sold of propylene oxide products had on your net sales for the Specialty Products segment as compared to the modest price increases for your ethylene oxide products for medical device sterilization. This is not meant to be an all-inclusive list of where improvements could be made to expand your explanations. See Item 303(a)(3) of Regulation S-K.

BCPC answered
We acknowledge the Commission’s comment and in future filings, the Company will revise its MD&A to include a more detailed quantification and the business reasons for changes between periods relating to sales and operating expense line items. The Company will include a disclosure similar to the following example in Future Filings:

Net Sales

Net sales for 2010 were $255,071, as compared with $219,438 for 2009, an increase of $35,633 or 16.2%. Net sales for the Specialty Products segment were $42,239 for 2010, as compared with $36,368 for 2009, an increase of $5,871 or 16.1%.
Rest of the answer

Approximately 65% of this increase in sales was derived from an increase in volumes sold of propylene oxide products, a result of our recent acquisition of a marketer and distributor of propylene oxide for use in the fumigation of certain nut meats and spice fumigation. The balance of the increased sales is principally a result of modest price increases, to partially offset rising raw material costs, and volume improvements for our ethylene oxide products for medical device sterilization. Net sales for the Food, Pharma & Nutrition segment were $41,994 for 2010 compared with $35,407 for 2009, an increase of $6,587 or 18.6%. This result was driven by a 23% sales increase in the food and nutrition sector. Increased volumes sold were responsible for 76% of this improvement while higher average selling prices, a result of favorable product mix along with some increased selling prices, made up the balance of this improvement. These increases were partially offset by lower sales of calcium products, which were down approximately 25%. Net sales of $170,838 were realized for 2010 for the Animal Nutrition & Health segment, as compared with $147,663 for the prior year comparable period, an increase of $23,175 or 15.7%. Global feed grade choline product sales improved by approximately 1%. Sales within North America improved approximately 3% over the prior year; however, overall North American produced feed grade choline declined slightly in conjunction with lower poultry production levels in the year. Exports of liquid and dry choline from our North American plants declined largely due to currency issues and, in combination with global competition, resulted in our declining to bid on certain international business. The ANH specialty ingredients, largely targeted to the ruminant and companion animal markets, realized 16.0% sales growth from the prior year comparable period, as some regional improvement in dairy economics supported greater demand for these products, particularly with strong sales of Reashure®, chelated minerals and Aminoshure®-L, our rumen protected lysine. Sales of industrial grade products being sold for various industrial applications, predominantly in North America, but also in Europe realized significant growth as volumes grew approximately 73% over the prior year and comprise approximately 26% of the sales in this segment for the year.

Operating Expenses

Operating expenses for 2010 were $28,267, as compared to $26,299 for 2009, an increase of $1,968 or 7.5%. This increase was primarily due to increased amortization and consulting costs totaling approximately $411 related to the Aberco acquisition, increased recruiting and relocation fees of approximately $258, a modest increase of employee headcount and additional compensation-related expenses totaling approximately $1,078, and increased consultancy fees of approximately $239 primarily incurred to study acquisition opportunities, partially offset by a reduction in outside contract research expense of approximately $81, principally due to the timing of these activities, and accounts receivable reserves for international accounts that were an expense/reserve item in the prior year comparable period totaling approximately $425. Operating expenses were 11.1% of sales or 0.9 percentage points less than the operating expenses as a percent of sales in last year's comparable period. During 2010 and 2009, the Company spent $3,190 and $3,298 respectively, on research and development programs, substantially all of which pertained to the Company’s Food, Pharma & Nutrition and Animal Nutrition & Health segments.

Read in the reply
In its next report

First report after the company's reply of Dec 28, 2011: 10-K filed Feb 29, 2012 ↗, against the 10-K filed Feb 28, 2011 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Liquidity and Capital Resources, page 18
SEC asked (3)
Given your significant foreign operations, please consider enhancing your liquidity disclosure in future filings to address the following:  Disclose the amount of foreign cash and short-term investments you have as compared to your total amount of cash and short-term investments as of December 31, 2010; and  Discuss the fact that if the foreign cash and short-term investments are needed for your operations in the
Rest of the question

U.S., you would be required to accrue and pay U.S. taxes to repatriate these funds but your intent is to permanently reinvest these foreign amounts outside the U.S. and your current plans do not demonstrate a need to repatriate the foreign amounts to fund your U.S. operations, if true. Refer to Item 303(a)(1) of Regulation S-K, SEC Release 33-8350 Section IV and Financial Reporting Codification 501.06.a.

BCPC answered
In accordance with the Staff's comment, in our future filings, we will expand our discussion within “Liquidity and Capital Resources” to clarify any significant cash and short-term investment balances held by our foreign subsidiaries. In addition, we will also disclose, if applicable, that we would need to accrue and pay taxes if the funds were repatriated and that we do not intend to repatriate the funds.
Rest of the answer

The Company will include a disclosure similar to the following example in future filings:

Cash

Cash and cash equivalents increased to $77,253 at December 31, 2010 from $46,432 at December 31, 2009 primarily resulting from the activity detailed below. At December 31, 2010, the Company had $2,269 of cash and cash equivalents held by our foreign subsidiaries. It is our intention to permanently reinvest these funds in our foreign operations by continuing to repay acquisition related debt, make additional plant related investments as needed and potentially invest in additional acquisitions; therefore, we do not currently expect to repatriate these funds in order to fund our U.S. operations or obligations. However, if these funds were to be needed for our operations in the U.S., we could be required to pay additional U.S. taxes to repatriate these funds. Working capital amounted to $100,144 at December 31, 2010 as compared to $59,197 at December 31, 2009, an increase of $40,947.

Read in the reply
In its next report

First report after the company's reply of Dec 28, 2011: 10-K filed Feb 29, 2012 ↗, against the 10-K filed Feb 28, 2011 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Item 8 – Financial Statements and Supplementary Data, page 24 · Note 12 – Segment Information, page 46
SEC asked (4)
Please disclose for each period presented the amount of long-lived assets attributed to your country of domicile, as well as attributed to all foreign countries in total. If assets in an individual foreign country are material, those assets should be disclosed separately. Refer to FASB ASC 280-10-50-41(b).
BCPC answered
In accordance with the Staff's comment, in our future filings, we will expand our disclosure to include the amount of long-lived assets attributed to our country of domicile, as well as attributed to all foreign countries in total. The Company will include a disclosure similar to the following example in future filings:
Read in the reply
In its next report

First report after the company's reply of Dec 28, 2011: 10-K filed Feb 29, 2012 ↗, against the 10-K filed Feb 28, 2011 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Form 10-Q for the Quarter Ended September 30, 2011
SEC asked (5)
Please address the above comments in your interim filings as well, as applicable.
BCPC answered
We agree to provide the additional disclosures or revisions as noted in our responses in our future filings with the Commission on 10-Q, as applicable.
Read in the reply
Signatures, page 31
SEC asked (6)
Your principal financial or chief accounting officer should also sign the Form 10-Q. Refer to Instruction G of Form 10-Q.
BCPC answered
We agree to include the additional signature in our future filings with the Commission on Form 10-Q.
Read in the reply
Form 8-K Filed June 22, 2011
SEC asked (7)
It does not appear that you have amended your Form 8-K to report your decision regarding the frequency of say-on-pay votes. The amended Form 8-K is generally required to be filed within 150 days after the shareholder meeting. Please advise.
BCPC answered
We acknowledge our oversight in filing this Form 8-K/A and assure the SEC that our internal procedures have been modified to assure prompt filing in future periods. The Company has filed a Form 8-K/A reporting its decision regarding the frequency of say-on-pay votes on December 15, 2011.

Balchem acknowledges that:

·

Balchem is responsible for the adequacy and accuracy of the disclosure in its filings;

Staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and

Balchem may not assert staff
Rest of the answer

comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Read in the reply

Also in this review: company letter, Dec 13, 2011, closing letter, 2011-12-29

Form 10-K for the Fiscal Year Ended December 31, 2009

2010-10-12 to 2010-11-29 · 14 questions · 2 letters from the SEC, 2 from the company
Review closed 2010-11-29
RevenueAcquisitionsLegal and contingenciesResults discussion (MD&A)Liquidity and cashGoodwill and impairmentCritical estimatesControls
Form 10-K for the Fiscal Year Ended December 31, 2009 · General
SEC asked (1)
Where a comment below requests additional disclosures or other revisions to be made, please show us in your supplemental response what the revisions will look like. These revisions should be included in your future filings, including your interim filings, if applicable.
BCPC answered
We agree to provide the additional disclosures or revisions as noted in the response below in our future filings with the Commission on Form 10-K and Form 10-Q, as applicable. Sample disclosures, for illustration purposes only, are included below as appropriate.
Read in the reply
Critical Accounting Policies · Long-Lived Assets, page 21
SEC asked (2)
In the interest of providing readers with a better insight into management’s judgments in accounting for goodwill, please disclose the following: • The reporting unit level at which you test goodwill for impairment and your basis for that determination; • How you weight each of the methods used to value goodwill, including the basis for that weighting; • How the methodologies used for valuing goodwill in the current
Rest of the question

year have changed since the prior year; and • To the extent that any of your reporting units have estimated fair values that are not substantially in excess of the carrying value and to the extent that goodwill for these reporting units, in the aggregate or individually, if impaired, could materially impact your operating results, please provide the following disclosures for each of these reporting units: • Identify the reporting unit; • The percentage by which fair value exceeds the carrying value as of the mostrecent step-one test; • The amount of goodwill; • A description of the assumptions that drive the estimated fair value; • A discussion of the uncertainty associated with the key assumptions. For example, to the extent that you have included assumptions in your discounted cash flow model that materially deviates from your historical results, please include a discussion of these assumptions; and • A discussion of any potential events and/or circumstances that could have a negative effect to the estimated fair value. If you have determined that the estimated fair value substantially exceeds the carrying value for all of your reporting units, please disclose this determination. Please also provide the above disclosures, as applicable, for any long-lived assets or asset groups for which you have determined that undiscounted cash flows is not substantially in excess of the carrying value and to the extent that the asset amounts, in the aggregate or individually, could materially impact your operating results or total shareholder’s equity. Please refer to Item 303 of Regulation S-K and Sections 216 and 501.14 of the SEC’s Codification of Financial Reporting Policies for guidance.

BCPC answered
We acknowledge the Staff’s comment and propose to include substantially the following expanded disclosure of our discussion of Impairment Analysis in our future filings with the Commission. The content of this disclosure will be applied prospectively.

Long-Lived Assets

Long-lived assets, such as property, plant, and equipment and intangible assets with finite lives, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
Rest of the answer

Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset, which is generally based on discounted cash flows.

Goodwill, which is not subject to amortization, is tested annually for impairment, and more frequently if events and circumstances indicate that the asset might be impaired. If an indicator of impairment exists, the Company determines the amount of impairment based on a comparison of the implied fair value of its goodwill to its carrying value. We also perform impairment analyses whenever events and circumstances indicate that goodwill or certain intangibles may be impaired.

In accordance with the ASC Topic 350, we test goodwill for impairment at the reporting unit level. We utilize our three operating segments as our goodwill reporting units as we have discrete financial information that is regularly reviewed by operating segment management and businesses within each segment have similar economic characteristics. For the year ended December 31, 2009, the Company’s three reporting units were Specialty Products; Food, Pharma & Nutrition; and Animal Nutrition & Health. We have historically assessed, and continue to assess, the fair value of our reporting units by solely utilizing the income approach, based on a discounted cash flow valuation model as the basis for our conclusions, as we feel this provides the most reliable valuation indicator based on our long term projections for each reporting unit. Our estimates of future cash flows include significant management assumptions such as revenue growth rates, operating margins, discount rates, estimated terminal value and future economic and market conditions. These valuation procedures are consistent with goodwill impairment tests performed in prior years. We completed our annual goodwill impairment test as of December 31, 2009, which indicated no impairment of goodwill, as the estimated fair values substantially exceeded the carrying values of each of our reporting units. In addition, there were no triggering events which required asset impairment reviews and the undiscounted cash flows associated with our property, plant and equipment and other long-lived intangible assets were well in excess of the carrying value of these asset classes.

Read in the reply
In its next report

First report after the company's reply of Nov 5, 2010: 10-K filed Feb 28, 2011 ↗, against the 10-K filed Mar 12, 2010 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Note 1. Business Description and Summary of Signfiicant Accounting Policies, page 35 · Revenue Recognition, page 35
SEC asked (3)
Please help us better understand how you recognize revenue by addressing the following: • Please disclose your revenue recognition policy separately for each of your revenue streams; • Please clarify whether there are multiple deliverables associated with your sales arrangements. For example, the sale of gas, such as ethylene oxide, may require the customer to rent the container which holds the gas.
Rest of the question

If so, please clarify in your disclosures your accounting for multiple deliverable arrangements. You should also identify each unit of accounting, how you determined it was appropriate to account for each unit of accounting separately, how you allocate amounts to each unit, and how you account for each unit. Refer to ASC 605-25, including the disclosure requirements of ASC 605-25-50; • Please clarify whether any special privileges or rights are given in your arrangements with distributors, including whether products are shipped to them on a consignment basis; and • You state that you follow the provisions of ASC Topic 605 which sets forth guidelines on the timing of revenue recognition based upon factors such as passage of title, installation, payments and customer acceptance. Please tell us whether there is installation involved with any of your products or whether there are customer acceptance terms in any of your arrangements. Refer to SAB Topic 13:A.3(b).

BCPC answered
We have reviewed our Revenue Recognition policy and agree to provide expanded disclosure in future filings. Please note that the Company does not sell products that require installation and therefore we have removed the reference from our disclosure. Also, the Company does not have any material sales arrangements with associated multiple deliverables. With regard to the Company’s arrangements with distributors, any shipments to distributors are treated as revenue transactions, and are not on consignment.
Rest of the answer

Our standard sales terms, which are set forth on our invoices, apply to our sales to distributors and end users. The price to be paid by the distributor is fixed and determinable. Sales terms are consistent for both end users and distributors, with the exception of payment terms, which are generally thirty days longer for distributors. Legal transfer of title passes to the distributor when the product is shipped to the distributor.

With respect to customer acceptance of our products, our customers may, through their quality programs, inspect our products before acceptance. Any product returned due to quality issues would result in the reversal of revenue in the period in which it occurred. However, the Company performs quality inspections before shipment, and the Company has a history of experiencing insignificant returns.

In future filings, the Company will expand its Revenue Recognition disclosure as follows:

Revenue Recognition

Revenue, for each of our business segments is recognized upon product shipment, passage of title and risk of loss, and when collection is reasonably assured. The Company reports amounts billed to customers related to shipping and handling as revenue and includes costs incurred for shipping and handling in cost of sales. Amounts received for unshipped merchandise are principally not recognized as revenue but rather they are recorded as customer deposits and are included in current liabilities. In instances of shipments made on consignment, revenue is deferred until a customer indicates to the Company that it has used the Company’s products. The Company does not charge its customers rental fees on cylinders or drums used to ship its products. In addition, the Company follows the provisions of ASC Topic 605, “Revenue Recognition” (incorporating the Securities and Exchange Commission’s (SEC) Staff Accounting Bulletin (SAB) No. 104, “Revenue Recognition”) which sets forth guidelines on the timing of revenue recognition based upon factors such as passage of title, payments and customer acceptance.

Read in the reply
In its next report

First report after the company's reply of Nov 5, 2010: 10-K filed Feb 28, 2011 ↗, against the 10-K filed Mar 12, 2010 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Note 2. Stockholders’ Equity · Stock-Based Compensation, page 41
SEC asked (4)
Please disclose whether any of your share-based payment awards have dividend rights. If they do have dividend rights, please also address the following: • Please disclose the terms of these rights, including whether they are nonforfeitable and participate on a one-for-one basis with holders of common stock; and • Please tell us what consideration you gave to ASC 260-10-45-61A as far as whether you should use the
Rest of the question

two-class method for determining earnings per share.

BCPC answered
We acknowledge the Staff’s comment and had previously determined that while the Company has some share-based payment awards that have non-forfeitable dividend rights that these awards have an immaterial impact as participating securities with regard to the calculation using the two-class method for determining earnings per share. These awards are restricted shares with non-forfeitable dividend rights and they participate on a one-for-one basis with holders of common stock.
Rest of the answer

In future filings, beginning with the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2010, the Company will modify its disclosure to include the aforementioned information.

Read in the reply
In its next report

First report after the company's reply of Nov 5, 2010: 10-K filed Feb 28, 2011 ↗, against the 10-K filed Mar 12, 2010 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Note 6. Intangible Assets with Finite Lives, page 47
SEC asked (5)
Given that your customer list intangible assets appear to be related to multiple acquisitions, please help us understand why all customer lists appear to be amortized on a straight-line basis over a ten year period. Please provide us with a breakdown of your customer lists by acquisition, which should include the gross and net carrying amount as of December 31, 2009 and June 30, 2010.
Rest of the question

For each significant customer list, please tell us how you determined the appropriate amortization period. Please also tell us how you determined it was appropriate to amortize the customer list on a straight-line basis and how this reflects the pattern in which you realize the economic benefits of the customer list. Given that it would appear you have customer attrition every year, please address why you would not expect to attain greater benefit from an acquired customer base in earlier versus later periods after acquisition. Please also address your consideration of whether sales in later periods may be more attributed to your ongoing sales efforts. Refer to ASC 350-30-35-1 through 3 and ASC 350-3035-6.

BCPC answered
The customer list intangible assets referred to in your comment principally reflect the customer relationships acquired with the Choline Chloride assets of Chinook Global Limited ("Chinook"). Choline Chloride is an essential nutrient for optimum animal growth, and is integral in building, regulating, and maintaining cell membrane integrity and porosity. Choline and Choline derivatives are also used in many other industrial applications. The acquired base of customers from the Chinook acquisition were principally North American customers.
Rest of the answer

Balchem integrated the acquisition into its existing Choline Chloride manufacturing businesses in Verona, Missouri and St. Gabriel, Louisiana.

We determine the useful lives of customer lists based principally upon historical customer sales attrition information and other customer-related factors. By way of background, Choline is found in many feedstuffs and its content has been standardized and reported by the National Research Council. However, it is generally accepted that feedstuffs alone cannot satisfy an animal's needs for Choline. Thus, the direct supplementation of animal diets with Choline Chloride products has become an economical means of providing additional quantities of this essential nutrient to growing animals. We expect that to be the case for the foreseeable future.

Customer attrition in the North American poultry market is relatively low (i.e. generally less than from 5%). Balchem has also experienced a very low customer attrition rate and any future customer attrition is not easily predictable. Low customer attrition primarily results from a combination of the following factors: first, that the dollar amount of Choline consumed by customers typically represents a small cost relative to other feed costs; second, Choline Chloride is considered by many to be an essential nutrient in poultry and swine production; and third, Balchem Corporation is the only producer of Choline Chloride in North America. While Choline Chloride is currently available from other global producers, in most instances these other sources of material are of either inferior quality or are not competitively priced. We do, however, believe that the quality of product produced by our competitors will eventually improve and/or a competitor may choose to construct a competitive plant in North America; therefore, we do not believe the useful life of the customer list could be considered to be indefinite. These factors all contribute to the minimal customer turnover in the North American marketplace we expect to experience. Based upon the above factors, while we believe that there will still be economic contributions at the end of ten years, they are more uncertain and therefore, it is the Company’s position that ten years is the best estimate for a useful life.

To monitor the continued benefits of our customer relationships, Balchem prepares a post-acquisition review for a three year period after completing an acquisition. Post-acquisition reviews compare the estimated operating results of the acquired business, including revenue, to those forecasted at the acquisition date. The loss of a significant number of customers would be identified through the business unit’s performance review and by the post-acquisition review. A loss of a significant number of customers would trigger a reassessment of our customer list amortization period and, if applicable, an impairment test. To date, our post-acquisition reviews have not resulted in our making any changes to our amortization period or caused us to perform additional impairment testing.

As to the amortization of the customer lists, we concluded use of the straight-line method was appropriate in the circumstances. Such conclusion was reached after considering the guidance of ASC 350-30-35-6 which states that an intangible asset should be amortized over its useful life using a method of amortization that reflects the pattern in which the economic benefits of the intangible asset are consumed or otherwise used up; however, if the pattern cannot be “reliably determined”, then straight-line amortization is appropriate. Based on the above, the Company believes that the straight-line method of amortization of customer relationship assets and the useful lives assigned to each of the customer relationship assets is appropriate. The Company has and shall continue to evaluate the remaining useful lives of its customer relationship intangible assets each reporting period to determine whether events and circumstances warrant a revision to the remaining periods of amortization.

Customer lists with finite lives at June 30, 2010 and December 31, 2009 are summarized as follows:

June 30, 2010

December 31, 2009

Acquisition

Gross

Carrying

Amount

Net

ABERCO

$

3,600

3,574

-

Read in the reply
In its next report

First report after the company's reply of Nov 5, 2010: 10-K filed Feb 28, 2011 ↗, against the 10-K filed Mar 12, 2010 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Note 11. Commitments and Contingencies, page 52
SEC asked (6)
Please tell us what consideration you gave to providing disclosures regarding the intellectual property patent suit filed against you by SODA Feed Ingredients, LLC in April 2009. Refer to ASC 450-20-50.
BCPC answered
The action commenced by SODA INGREDIENTS, LLC was a Declaratory Judgment Action which sought clarification from a Federal Court regarding an on-going patent infringement issue that Balchem asserted against SODA. Notwithstanding the fact that Balchem subsequently settled this litigation with SODA, we considered the risks associated with this litigation to be insignificant because of the size of the particular product market associated with the patent in question and because of the strength of our legal position.

Balchem acknowledges that:

Balchem is responsible for the adequacy and accuracy
Rest of the answer

of the disclosure in its filings;

Staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and

Balchem may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Read in the reply
In its next report

First report after the company's reply of Nov 5, 2010: 10-K filed Feb 28, 2011 ↗, against the 10-K filed Mar 12, 2010 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Form 10-Q for period ended June 30, 2010
SEC asked (7)
Please address the above comments in your interim filings as well.
BCPC answered

No numbered answer found in the reply. Read the reply ↗

Form 10-K for the Fiscal Year Ended December 31, 2009 · General
SEC asked (1)
Where a comment below requests additional disclosures or other revisions to be made, please show us in your supplemental response what the revisions will look like. These revisions should be included in your future filings, including your interim filings, if applicable.
BCPC answered
We agree to provide the additional disclosures or revisions as noted in the response below in our future filings with the Commission on Form 10-K and Form 10-Q, as applicable. Sample disclosures, for illustration purposes only, are included below as appropriate.
Read in the reply
Note 1. Business Description and Summary of Signfiicant Accounting Policies, page 35 · Revenue Recognition, page 35
SEC asked (2)
We note your response to prior comment 3. Please tell us the terms of your acceptance provisions. Please tell us what consideration you gave to SAB Topic 13:A.3(b) in determining that revenue should be recorded prior to acceptance. Please specifically address your consideration of each of the questions and answers included in this section regarding customer acceptance provisions.
BCPC answered
Revenue is recognized when title and risk of loss have transferred to the customer and when contractual terms have been fulfilled. Transfer of title and risk of loss occurs when the product is delivered in accordance with the contractual shipping terms. The Company advises the Staff that it applies the Staff’s guidance for evaluating the appropriateness of revenue recognition when arrangements include customer acceptance provisions.
Rest of the answer

The vast majority of our arrangements with customer acceptance provisions fall in the category described in Question 1 of SAB Topic 13.A.3.bcategory (c), acceptance provisions based on seller-specified objective criteria. In instances where contractual terms include a provision for customer acceptance, revenue is recognized when either (i) the Company has previously demonstrated that the product meets the specified criteria for contracts with acceptance provisions based on seller-specified objective criteria or (ii) upon formal acceptance received from the customer for contracts with acceptance provisions where the product has not been previously demonstrated to meet customer-specified objective criteria.

Note 2. Stockholders' Equity

Stock-Based Compensation. page 41.

Read in the reply
In its next report

First report after the company's reply of Nov 22, 2010: 10-K filed Feb 28, 2011 ↗, against the 10-K filed Mar 12, 2010 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Note 2. Stockholders’ Equity · Stock-Based Compensation, page 41
SEC asked (3)
We note your response to prior comment 4. Please help us understand how you determined that the share-based payment awards that have non-forfeitable dividend rights have an immaterial impact with regard to the calculation of earnings per share using the two-class method.
Rest of the question

In this regard, please tell us the earnings per share amounts you would have reported for each of the three years ended December 31, 2009 and the nine months ended September 30, 2010 if you had accounted for these awards as participating securities. Refer to ASC 260-10-45-61A.

BCPC answered
For each of the three years ended December 31, 2009 and the nine months ended September 30, 2010, the Company has presented below the earnings per share amounts that would have been reported if the Company had accounted for its share-based payment awards with non-forfeitable dividend rights as participating securities.
Read in the reply
In its next report

First report after the company's reply of Nov 22, 2010: 10-K filed Feb 28, 2011 ↗, against the 10-K filed Mar 12, 2010 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Note 6. Intangible Assets with Finite Lives, page 47
SEC asked (4)
We note your response to prior comment 5. Approximately 87% of your customer lists at December 31, 2009 and approximately 76% of your customer lists at June 30, 2010 are related to Chinook Global Limited. Please provide us with a comprehensive analysis of how you arrived at a ten year amortization period for this customer list.
Rest of the question

Please provide us with a summary of the analysis performed to arrive at this amortization period. Given that it would appear you have customer attrition every year, we expect that that you would attain greater benefit from the acquired customer base in earlier versus later periods after acquisition. We also expect that a sizeable portion of your sales in later periods would be attributed to your ongoing sales efforts. Please also explain how you compensated for these factors in your selection of a ten year amortization period since you are using the straight-line method of amortization rather than an accelerated method. Refer to ASC 350-30-35-1 through 3 and ASC 350-30-35-6.

BCPC answered
We determine the useful lives of customer lists based upon how the asset is expected to contribute directly or indirectly to our future cash flows giving consideration to historical customer sales attrition and other factors that could have an impact on the expected life. Our conclusions were reached after giving consideration to the guidance provided in ASC 350-30-35-1 through 3 and ASC 350-30-35-6.

The customer list intangible asset, referred to in your comment letter, pertains to the customer relationships acquired with the Choline Chloride assets of Chinook Global Limited.
Rest of the answer

To properly determine the amortization period for the customer relationships asset, we performed a customer attrition analysis. It is important to note that Balchem Corporation has been a producer and marketer of Choline Chloride since 2001 and therefore had an ability to evaluate customer attrition in the North American poultry market based upon its existing business in accordance with ASC 350-30-35-3-d. Measurement of customer attrition was done with a base period of 2001 through 2007, and included all of our then North American Choline Chloride customers. Our calculation of customer attrition in the North American poultry market in 2007 concluded that attrition was relatively low (i.e. generally less than 5%). We determined that a similar low rate of attrition could be projected going forward due to our being the only remaining producer of Choline Chloride in North America in conjunction with the expectation of continued product demand resulting from our knowledge and understanding of the well documented nutritional value the product provides to the end users. Our projections did not forecast significant growth in later years due to the fact that upon completion of the transaction, Balchem would already be supplying the vast majority of the choline demand in North America and minimal organic growth was being projected for the end markets we serve. In addition, we also gave consideration to ASC 350-30-35-3-e and the potential effects of obsolescence, demand, competition, and other economic factors. With respect to obsolescence and demand, the dollar amount of Choline consumed by customers typically represents a small cost relative to other feed costs. The product is considered by many to be an essential nutrient in poultry and swine production and we are not aware of a technology or competitive product that would result in its obsolescence. From a competitive perspective, Balchem Corporation was and remains the only producer of Choline Chloride in North America. While Choline Chloride was available from other global producers, in most instances those other sources of material were of either inferior quality or were not competitively priced. We did, however, believe that the quality of product produced by our competitors would eventually improve and/or a competitor would choose to construct a competitive plant in North America; therefore, we did not conclude that the useful life of the customer list could be considered to be indefinite.

In accordance with ASC 350-30-35-6, if an intangible asset has a finite useful life, but the precise length of that life is not known, that intangible asset shall be amortized over the best estimate of its useful life. The following assumptions were used in arriving at our estimate of a ten year life:

·

Existing contracts had a remaining life of one year.

Balchem to offer contract extensions at expiring terms for an additional two years.

Historical attrition rate of our existing customer base since 2001 was less than 5% in combination with there being no other producer of product in North America would result in minimally, an additional seven years of life.

Based on the aforementioned factors, we believed that there would still be economic contributions at the end of ten years; however, they would be more uncertain due to the possibility of greater competition, and therefore, it was, and is the Company’s position that ten years is the best estimate for a useful life. With respect to the method of amortization, it shall reflect the pattern in which the economic benefits of the intangible asset are consumed or otherwise used up. If that pattern cannot be reliably determined, a straight-line amortization method shall be used. Due to the fact that there was no expectation of significant attrition or growth per our customer analysis, we concluded that a straight line amortization of the asset was most reasonable.

Read in the reply
In its next report

First report after the company's reply of Nov 22, 2010: 10-K filed Feb 28, 2011 ↗, against the 10-K filed Mar 12, 2010 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Note 11. Commitments and Contingencies, page 52
SEC asked (5)
We note your response to prior comment 6. In order to help us better understand how you determined the matter related to SODA Ingredients, LLC was insignificant, please tell us the terms of the settlement including any amounts that you were required to pay.
BCPC answered
This matter was amicably settled by the parties and the litigation was dismissed. Balchem was not required to pay any monies, nor did Balchem incur any liability, as a result of the settlement.
Read in the reply
In its next report

First report after the company's reply of Nov 22, 2010: 10-K filed Feb 28, 2011 ↗, against the 10-K filed Mar 12, 2010 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Form 10-Q for period ended September 30, 2010
SEC asked (6)
Please address the above comments in your interim filings as well.
BCPC answered
We acknowledge the Staff’s comment and will incorporate our responses in our interim filings.
Read in the reply
Item 4. Controls and Procedures, page 30
SEC asked (7)
Based upon management’s evaluation, the Chief Executive Officer and the Chief Financial Officer have concluded that, as of the end of such period, your disclosure controls and procedures were effective in identifying the information required to be disclosed in the periodic reports filed with the Securities and Exchange Commission, including this Quarterly Report on Form 10-Q, and ensuring that such information is
Rest of the question

recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. This is an incomplete definition of disclosure controls and procedures per Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Please revise your definition to also clarify, if true, that your disclosure controls and procedures were effective to ensure that information required to be disclosed by you in the reports that you file or submit under the Exchange Act is accumulated and communicated to your management, including your principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Alternatively, you may simply conclude that your disclosure controls and procedures are effective or ineffective, whichever the case may be. Please also confirm to us that your disclosure controls and procedures were effective as of September 30, 2010 when evaluating based on the complete definition of disclosure controls and procedures.

BCPC answered
Be advised that we will replace the previous section (a) of “Item 4. Controls and Procedures” with the following:

(a)

Evaluation of Disclosure Controls and Procedures

As required by Rule 13a-15 under the Securities Exchange Act of 1934 (the “Exchange Act”), we carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as of the end of the period covered by this report on Form 10-Q.
Rest of the answer

This evaluation was carried out under the supervision and with the participation of our management, including our President and Chief Executive Officer and our Chief Financial Officer. Based upon that evaluation, management concluded that our disclosure controls and procedures are effective to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is accumulated and communicated to management (including the chief executive officer and chief financial officer) to allow timely decisions regarding required disclosure and that our disclosure controls and procedures are effective to give reasonable assurance that the information required to be disclosed by us in reports that we file under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission.

Furthermore, we also confirm that our disclosure controls and procedures were effective as of September 30, 2010, when evaluated based upon the revised definition of disclosure controls and procedures above.

Balchem acknowledges that:

Balchem is responsible for the adequacy and accuracy of the disclosure in its filings;

Staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and

Balchem may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Read in the reply
In its next report

First report after the company's reply of Nov 22, 2010: 10-K filed Feb 28, 2011 ↗, against the 10-K filed Mar 12, 2010 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: request for more time, Oct 18, 2010, closing letter, 2010-11-29

Form 10-K for the year ended December 31, 2008

2009-12-30 to 2010-02-12 · 14 questions · 1 letter from the SEC, 1 from the company
Review closed 2010-02-12
Executive payRisk factorsDebtLegal and contingenciesResults discussion (MD&A)Liquidity and cash
Business · Intellectual Property, page 3
SEC asked (1)
In future filings, please disclose the duration of your patents. We note your statement here that you believe that certain of your patents, in the aggregate, are advantageous to your business but that no single patent or related group of patents is currently so material to you that the expiration or termination of any single patent or group of patents would materially affect your business.
Rest of the question

We also note, however, the risk factor in which you state that there may be an adverse effect on our business and financial results if you are unable to protect all of your intellectual property rights, or if you are found to be infringing the intellectual property rights of others. Please refer to Item 101(c)(iv) of Regulation S-K.

BCPC answered
In future filings with the SEC beginning with the Form 10-K to be filed for the period ended December 31, 2009, the Company will disclose the duration of its patents and amend/clarify its disclosure regarding risk associated with its intellectual property.

Competition, page 3

-------------------
Read in the reply
In its next report

First report after the company's reply of Jan 29, 2010: 10-K filed Mar 12, 2010 ↗, against the 10-K filed Mar 12, 2009 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Competition, page 3
SEC asked (2)
In future filings, if known or reasonably available to you, please disclose an estimate of the number of your competitors as well as your competitive position. Please refer to Item 101(c)(x) of Regulation S-K.
BCPC answered
We are not aware of reliable statistical data that would make disclosure of the percentage of the market that the Company has versus other major competitors practicable. We will, however, include disclosure to such effect in the future should reliable information become available to us.

In future filings with the SEC beginning with the Form 10-K to be filed for the period ended December 31, 2009, the Company will address its competitive position.

Risk Factors

------------

Our success depends in large part on our key personnel.
Rest of the answer

page 9

--------------------------------------------------------------

Read in the reply
Risk Factors · Our success depends in large part on our key personnel, page 9
SEC asked (3)
This risk factor appears to be generic and applicable to any company and industry. In future filings, please remove or revise the risk factor to explain in greater detail the particular risks you face from the loss of senior executives. Litigation could be costly and can adversely affect our business and financial results,
BCPC answered
The Company agrees with the Staff that this risk factor as written is generic and will remove it from future filings.

Litigation could be costly and can adversely affect our business and

-------------------------------------------------------------------------- financial results.page 9

------------------------
Read in the reply
In its next report

First report after the company's reply of Jan 29, 2010: 10-K filed Mar 12, 2010 ↗, against the 10-K filed Mar 12, 2009 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Risk Factors · Our success depends in large part on our key personnel, page 9
SEC asked (4)
In future filings, please revise this risk factor to explain how the risks discussed are currently material to you.
BCPC answered
As the Company is not currently involved in any material litigation, the Company has concluded that this risk factor as written is generic and will remove it from future filings. If the Company were to become involved in any litigation, management would have to assess whether or not such litigation would likely have a material adverse effect on the

Company's consolidated financial condition or results of operations and would readdress whether to include an appropriate risk factor.

Management's Discussion and Analysis of Financial Condition and Results of

Operations Fiscal Year 2008
Rest of the answer

compared to Fiscal Year 2007, page 15

-----------------------------------------------------------------

Read in the reply
In its next report

First report after the company's reply of Jan 29, 2010: 10-K filed Mar 12, 2010 ↗, against the 10-K filed Mar 12, 2009 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Management’s Discussion and Analysis of Financial Condition and Results of Operations · Fiscal Year 2008 compared to Fiscal Year 2007, page 15
SEC asked (5)
Please revise your MD&A in future filings to provide comprehensive explanations for changes in consolidated cost of sales and/or gross margin between the periods presented. Please show us in your supplemental response what your proposed revisions will look like.
BCPC answered
In future filings with the SEC beginning with the Form 10-K to be filed for the period ended December 31, 2009, the Company will include within Management's Discussion and Analysis a separate discussion of Gross

Margin to provide a more comprehensive analysis of the reasons for fluctuations between periods. Our proposed revision is as follow:

Gross Margin

Gross margin for 2008 increased to $52,578 compared to $46,930 for

2007, an increase of 12.0%, due largely to the above-noted increase in sales.
Rest of the answer

Gross margin percentage for 2008 was 22.7%, as compared to 26.6% for 2007, as our margin percentage was unfavorably affected by product mix and higher petro-chemical derivative raw materials and energy costs. Gross margin percentage for the specialty products segment decreased slightly primarily due to rising raw material costs. Gross margin percentage in the encapsulated / nutritional products segment increased 0.3% as margins were favorably affected by increased production, a result of greater sales volume as described above. Gross margin percentage in Animal Nutrition and

Health increased 15.3% and was favorably affected by increased production volumes. This favorable impact was partially offset by higher petro-chemical derivative raw material and energy costs.

Contractual Obligations, Page 18

--------------------------------

Read in the reply
In its next report

First report after the company's reply of Jan 29, 2010: 10-K filed Mar 12, 2010 ↗, against the 10-K filed Mar 12, 2009 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Contractual Obligations, Page 18
SEC asked (6)
Please revise your table of contractual cash obligations in future filings to include estimated interest payments on your debt as a separate line item. Because the table is aimed at increasing transparency of cash flow, we believe these payments should be included in the table. Please also disclose any assumptions you made to derive these amounts. Please show us in your supplemental response what your proposed
BCPC answered
In future filings with the SEC beginning with the Form 10-K to be filed for the period ended December 31, 2009, the Company will revise its table of contractual cash obligations to include estimated interest payments on debt as a separate line item. Our proposed revision is as follow:

Contractual Obligations

-----------------------

The Company's contractual obligations and debt obligations, excluding revolver borrowings, as of December 31, 2008, are summarized in the table below:

---------------------------------------------------------------------------------------------------

Payments
Rest of the answer

due by period

-------------------------------------------------------------

Less than More than

Contractual Obligations Total 1 year 1-3 years 3-5 years 5 years

Long-term debt obligations $ 9,531 $ 2,860 $ 6,671 $ -- $ --

Interest payment obligations (1) 1,042 350 482 203 7

Operating lease obligations (2) 2,590 1,128 894 347 221

Purchase obligations (3) 8,048 8,048 -- -- --

Total $ 21,211 $ 12,386 $ 8,047 $ 550 $ 228

(1) Includes interest payments on long-term debt obligations based on interest and foreign currency rates at December 31, 2008. It is assumed that the European Term Loan (as defined in Financing

Activities below) will be refinanced with similar terms and that there will be no prepayments of principal.

(2) Principally includes obligations associated with future minimum non-cancelable operating lease obligations (including the headquarters office space entered into in 2002).

(3) Principally includes open purchase orders with vendors for inventory not yet received or recorded on our balance sheet.

The table above excludes a $581 liability for uncertain tax positions, including the related interest and penalties, recorded in accordance with the Financial Accounting Standards Board's Interpretation No. 48,

"Accounting for Uncertainty in Income Taxes -- an interpretation of FAS

Statement No. 109" ("FIN 48") as we are unable to reasonably estimate the timing of settlement, if any.

Read in the reply
In its next report

First report after the company's reply of Jan 29, 2010: 10-K filed Mar 12, 2010 ↗, against the 10-K filed Mar 12, 2009 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Financing Activities, page 19
SEC asked (7)
Please revise your future filings to disclose here or elsewhere in the filing the specific terms of any material debt covenants in your debt agreements. Please also revise your future filings to indicate if you were in compliance with your debt covenants during the periods presented in your filing. Please show us in your supplemental response what your proposed revisions will look like.
BCPC answered
In future filings with the SEC beginning with the Form 10-K to the specific terms of any material debt covenants in our debt agreements.

Our proposed revision within the Financing Activities section is as

Significant financial covenants in our loan agreements include maintaining at certain levels our Current Ratio, Funded Debt Ratio, and a Fixed Charge

Coverage Ratio. We were in compliance with all covenants related to our loan agreements as of December 31, 2008 and we expect to be in compliance with all covenants during fiscal 2009.
Rest of the answer

Our loan agreements require compliance with all of the covenants defined in the agreement. If we were out of compliance with any debt covenant required by our loan agreements following the applicable cure period, our lender could terminate its commitment, unless we successfully negotiate a covenant waiver.

Consolidated Financial Statements

---------------------------------

General

-------

Read in the reply
In its next report

First report after the company's reply of Jan 29, 2010: 10-K filed Mar 12, 2010 ↗, against the 10-K filed Mar 12, 2009 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Consolidated Financial Statements · General
SEC asked (8)
Please revise your future filings to disclose comprehensive income and all components for each period presented. Items included in comprehensive income should be classified based on their nature. Please refer to paragraphs 14, 17, and 22 of SFAS 130. Please show us in your supplemental response what your proposed
BCPC answered
In future filings with the SEC beginning with the Form 10-K to comprehensive income and all components for each period presented. Our proposed revision is as follow:

BALCHEM CORPORATION

Consolidated Statements of Stockholders' Equity

Years Ended December 31, 2008, 2007 and 2006

(Dollars in thousands, except share and per share data)

Accumulated

Total Compre- Other Additional

Stockholders' hensive Retained Comprehensive Common Stock Paid-in Treasury Stock

Equity Income Earnings Income Shares Amount Capital Shares Amount

--------- --------- --------- --------- --------- ---------
Rest of the answer

--------- --------- ---------

Balance - December 31, 2005 $ 60,933 $ 53,306 $ -- 17,461,447 $ 776 $ 8,008 (96,024) $ (1,157)

Comprehensive Income:

Net earnings 12,278 $ 12,278 12,278 -- -- -- -- -- --

---------

Other Comprehensive Income -- -- -- -- -- -- -- -- --

Comprehensive Income -- $ 12,278 -- -- -- -- -- -- --

=========

Dividends ($.09 per share) (1,596) (1,596) -- -- -- -- -- --

Shares issued under employee benefit plans and other 334 -- -- 1,079 -- 70 21,933 264

Shares and options issued under stock option plans and an income tax benefit of $878 3,220 -- -- 271,323 12 2,315 74,091 893

Adjustment to initially apply FASB

Statement No. 158, net of tax 193 -- 193 -- -- -- -- --

--------- --------- --------- --------- --------- --------- --------- ---------

Balance - December 31, 2006 75,362 63,988 193 17,733,849 788 10,393 -- --

Net earnings 16,118 $ 16,118 16,118 -- -- -- -- -- --

Other comprehensive income, net of tax:

Net change in pension asset/liability, net of taxes of $26 (43) (43) -- -- -- -- -- -- --

Other Comprehensive Income -- (43) -- (43) -- -- -- -- --

Comprehensive Income -- $ 16,075 -- -- -- -- -- -- --

Dividends ($.11 per share) (1,975) (1,975) -- -- -- -- -- -- benefit plans and other 379 -- -- 20,869 1 378

Shares and options issued under -- -- income tax benefit of $677 3,530 -- -- 224,635 15 3,515 -- --

Cumulative effect of adjustment from adoption of FIN 48 (291) (291)

Balance - December 31, 2007 93,080 77,840 150 17,979,353 804 14,286 -- --

Net earnings 19,050 $ 19,050 19,050 -- -- -- -- -- -- of taxes of $8 48 48 -- -- -- -- -- -- --

Translation adjustments (206) (206) -- -- -- -- -- -- --

Other Comprehensive Income -- (158) -- (158) -- -- -- -- --

Comprehensive Income -- $ 18,892 -- -- -- -- -- -- --

Dividends ($.11 per share) (2,008) (2,008) -- -- -- -- -- -- benefit plans and other 406 -- -- 17,218 1 405 -- -- income tax benefit of $672 4,136 -- -- 252,776 18 4,118 -- --

Balance - December 31, 2008 $ 114,506 $ 94,882 $ (8) 18,249,347 $ 823 $ 18,809 -- $ --

========= ========= ========= ========= ========= ========= ========= =========

DEFINITIVE PROXY STATEMENT ON SCHEDULE 14A FILED APRIL 28. 2009

---------------------------------------------------------------

Compensation Committee, page 9

------------------------------

Read in the reply
DEFINITIVE PROXY STATEMENT ON SCHEDULE 14A FILED APRIL 28, 2009 · Compensation Committee, page 9
SEC asked (9)
The precise nature of your benchmarking is not clear. Because comparative pay information appears to be material to your compensation policies and decisions, in future filings please identify the benchmark and its components (including peer group companies). If you have benchmarked various elements of your compensation against different benchmarking groups, please identify the companies that comprise each group.
Rest of the question

Please include a discussion of where actual payments of each element of compensation fell for each named executive officer within targeted parameters. To the extent actual compensation was outside a targeted percentile range, please explain why. Refer to Item 402(b)(2)(xiv) of Regulation S-K and Question 118.05 of the Division of Corporation Finance’s Compliance & Disclosure Interpretations.

BCPC answered
We acknowledge the Staff's comments and the Company will endeavor to provide additional detail regarding its benchmarking process and will also include a discussion of where actual payments of each element of compensation fell for each named executive officer within targeted parameters. In addition, the Company will disclose the constituent companies of surveys that we use for benchmarking purposes.

Base Salary, page 10

--------------------
Read in the reply
In its next report

First report after the company's reply of Jan 29, 2010: 10-K filed Mar 12, 2010 ↗, against the 10-K filed Mar 12, 2009 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Base Salary, page 10
SEC asked (10)
We note that the Compensation Committee considers a number of factors in its annual review of base salaries for named executive officers. In future filings, to the extent base salaries and other elements of compensation (such as cash based incentives) are correlated with the achievement of certain individual and corporate objectives and performance goals, please discuss the specific items of individual performance
Rest of the question

used to determine various elements of compensation for each named executive officer. Please see Item 402(b)(2)(v) and (vii) of Regulation S-K. Additionally, the disclosure in this section regarding the rationale for the salary increases is too general. In particular, there is little discussion of how the general factors noted translated into the salary increases. Please refer to Item 402(b)(2)(ix) of Regulation S-K. The compensation discussion and analysis should be sufficiently precise to identify material differences in compensation policies with respect to individual named executive officers. Refer to Section II.B.1. of Release No. 338732A.

BCPC answered
We acknowledge the Staff's comments and the Company will provide additional detail regarding any of the Company's current or future compensation programs that are based on objective and performance goals.

To the extent there are objective and performance goals, the Company agrees to quantify the formulated targets established by the Committee as well as the Company's actual performance relative to those targets. In addition, we will provide additional disclosure regarding the general factors considered by the Compensation Committee in making executive compensation decisions.
Read in the reply
In its next report

First report after the company's reply of Jan 29, 2010: 10-K filed Mar 12, 2010 ↗, against the 10-K filed Mar 12, 2009 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Cash Based Incentives, page 12
SEC asked (11)
We note that the Compensation Committee determined that the company failed to meet its 2008 EBITDA goal, however, the Compensation Committee made discretionary cash bonus awards to certain named executive officers. In future filings, please disclose the factors the Compensation Committee used to determine the amount of the award given to each named executive officer that received such discretionary cash bonus award.
Rest of the question

Please refer to Item 402(b)(vi) of Regulation S-K.

BCPC answered
We acknowledge the Staff's comments and the Company will, in future filing, disclose the factors the Compensation Committee used to determine the amount of the award given to each named executive officer that received a discretionary cash bonus award.

Equity Based Compensation, page 12

----------------------------------
Read in the reply
In its next report

First report after the company's reply of Jan 29, 2010: 10-K filed Mar 12, 2010 ↗, against the 10-K filed Mar 12, 2009 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Equity Based Compensation, page 12
SEC asked (12)
Your compensation discussion and analysis provides minimal, if any, analysis as to how the ultimate level of equity awards was determined and how the performance of the named executives was measured. In future filings, for each named executive officer, please provide a substantive analysis and insight into why the compensation committee determined that the levels of equity compensation were appropriate in light of
Rest of the question

the factors considered in deriving those payouts. Please refer to Items 402(b)(2)(i)-(vii) of Regulation S-K.

BCPC answered
We acknowledge the Staff's comments and the Company will, in future filings, provide a substantive analysis and insight into why the compensation committee determined that the levels of equity compensation were appropriate in light of the factors considered in deriving those payouts.

Termination of Employment and Change of Control Arrangements, page 19

---------------------------------------------------------------------
Read in the reply
In its next report

First report after the company's reply of Jan 29, 2010: 10-K filed Mar 12, 2010 ↗, against the 10-K filed Mar 12, 2009 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Termination of Employment and Change of Control Arrangements, page 19
SEC asked (13)
In future filings, please describe and explain how the appropriate payment and benefit levels are determined under the various circumstances that trigger payments or provision of benefits under employment agreements and change of control arrangements.
Rest of the question

Also, discuss the rationale for decisions made in connection with these arrangements and how they fit into your overall compensation objectives and affect the decisions you made regarding other compensation elements. See paragraphs (b)(1)(v) and (j)(3) of Item 402 of Regulation S-K.

BCPC answered
We acknowledge the Staff's comments and the Company will, in future filings, describe and explain how the appropriate payment and benefit levels are determined under the various circumstances that trigger payments or provision of benefits under employment agreements and change of control arrangements.
Rest of the answer

In addition, we will also discuss the rationale for decisions made in connection with these arrangements and how they fit into our overall compensation objectives and affect the decisions made regarding other compensation elements.

Related Party Transactions, page 23

-----------------------------------

Read in the reply
In its next report

First report after the company's reply of Jan 29, 2010: 10-K filed Mar 12, 2010 ↗, against the 10-K filed Mar 12, 2009 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Related Party Transactions, page 23
SEC asked (14)
In future filings, pursuant to paragraph (b) of Item 404 of Regulation S-K, please describe your policies and procedures for review, approval, and ratification of any transaction required to be disclosed under paragraph (a) of Item 404. This includes a discussion of the standards to be applied pursuant to such policies and procedures.
Rest of the question

* * * * Please respond to these comments with in 10 business days or tell us when you will provide us with a response. Please provide us with a response letter that keys your responses to our comments and provides any requested information. Detailed letters greatly facilitate our review. Please furnish your response on EDGAR as a correspondence file. Please understand that we may have additional comments after reviewing your responses to our comments.

BCPC answered
We acknowledge the Staff's comments and the Company will, in future filings, describe its policies and procedures for review, approval, and ratification of any transaction required to be disclosed under paragraph (a) of Item 404 including, a discussion of the standards to be applied pursuant to such policy and procedure.

Balchem acknowledges that:

o Balchem is responsible for the adequacy and accuracy of the disclosure in its filings;

o Staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing;
Rest of the answer

and o Balchem may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Read in the reply
In its next report

First report after the company's reply of Jan 29, 2010: 10-K filed Mar 12, 2010 ↗, against the 10-K filed Mar 12, 2009 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2010-02-12

Letters without questions

Other letters

UPLOAD and CORRESP
1 other letter: notices that a filing will not be reviewed, requests to declare a registration effective, and the like
  • Jan 29, 2008 · SEC: review completed · Form 10-K for the fiscal year ended December 31, 2006 · Proxy Statement on Schedule...

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 17 letters filed since 2008-01-29. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BCPC/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.